Abstract
Description
The Bacterial Partnering Terms and Agreements report provides comprehensive
understanding and unprecedented access to the bacterial partnering deals and
agreements entered into by the worlds leading healthcare companies.
- Trends in bacterial partnering deals
- Average deal terms for headline, upfront and royalty by stage of
development
- Bacterial partnering agreement structure
- Bacterial partnering contract documents
- Top bacterial deals by value
- Most active bacterial dealmakers
The Bacterial Partnering Terms and Agreements report provides comprehensive
understanding and unprecedented access to the bacterial partnering deals and
agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why
companies enter bacterial partnering deals. The majority of deals are
discovery or development stage whereby the licensee obtains a right or an
option right to license the licensors bacterial technology. These deals tend
to be multicomponent, starting with collaborative R&D, and commercialization
of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This report contains over 1,000 links to online copies of actual bacterial
deals and contract documents as submitted to the Securities Exchange
Commission by companies and their partners. Contract documents provide the
answers to numerous questions about a prospective partner's flexibility on a
wide range of important issues, many of which will have a significant impact
on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of bacterial
dealmaking and business activities.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in bacterial dealmaking since
2007 covering trends by year, deal type, stage of development, technology type
and therapeutic indication. In addition the chapter includes an analysis of
financial deal terms by stage at signing covering headline value, upfront
payment, milestone payments and royalty rates. Analysis includes median values
and distribution of values for each stage of development.
Chapter 3 provides a review of the leading bacterial deals since 2007. Deals
are listed by headline value, signed by bigpharma, most active bigpharma, and
most active of all biopharma companies. Where the deal has an agreement
contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of bacterial deals,
as well as contract documents available in the public domain. Where available,
each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
Chapter 5 provides comprehensive access to all bacterial deals since 2007
where a deal contract is available, providing the user with direct access to
contracts as filed with the SEC regulatory authorities. Each deal title links
via Weblink to an online version of the deal record contract document,
providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all bacterial partnering deals
signed and announced since 2007. The chapter is organized by specific
infectives therapy focus. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all
bacterial partnering deals signed and announced since 2007. The appendices are
organized by company A-Z, stage of development at signing, deal type
(collaborative R&D, co-promotion, licensing etc) and technology type. Each
deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract
document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in bacterial partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
bacterial technologies and products.
Report scope
Bacterial Partnering Terms and Agreements is intended to provide the reader
with an in-depth understanding and access to bacterial trends and structure of
deals entered into by leading companies worldwide.
- Bacterial Partnering Terms and Agreements includes:
- Trends in bacterial dealmaking in the biopharma industry since 2007
- Analysis of bacterial deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of bacterial deal contract documents
- Comprehensive access to over 1,000 bacterial deal records
- The leading bacterial deals by value since 2007
- Most active bacterial dealmakers since 2007
In Bacterial Partnering Terms and Agreements, available deals and contracts
are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
The Bacterial Partnering Terms and Agreements report provides comprehensive
access to available deals and contract documents for over 1,000 bacterial
deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise bacterial rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Bacterial Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of bacterial deal trends since 2007
- Access bacterial deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between bacterial partner companies
- Comprehensive access to over 1,000 links to actual bacterial deals entered
into by the world's biopharma companies
- Indepth review of bacterial deals entered into by the leading fifty
bigpharma companies
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner bacterial opportunities
- Uncover companies actively partnering bacterial opportunities
Bacterial Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 801 Pages and the price starts from US $ 1995.
The contents of this page may be different from the latest version. Please contact us for details.
